The Protocol Management Office (PMO) provides a centralized resource to support the activation and management of all cancer treatment trials conducted at Fox Chase Cancer Center (FCCC), as well as selected prevention, imaging and data/sample collection trials. The PMO also provides scientific and technical review, ensures compliance with regulatory guidelines and standards, manages patient registration, treatment and data management, reporting to outside sponsors and communication with principal investigators and statisticians and collects and prepares pharmacokinetic and genomic samples for processing at FCCC or for shipping to outside sponsors. Sixty-eight investigators have opened clinical trials through the PMO during the last grant period, including 58 with peer-reviewed funding. Investigator Use over the past five years represents use for all five CCSG Programs. Additionally, all investigators at the Center have access to the Protocol Support Laboratory (PSL), a centralized laboratory for sample collection and processing, and the Protocol Specific Monitoring System for study evaluation and monitoring. During a time of reorganization at the Center, institutional support has been provided to several areas to improve and expand key areas in support of the clinical trials program. Specifically, the regulatory affairs team has been expanded to take on additional responsibilities in support of investigators at the Center;the informatics platform was expanded to additional outside affiliates for tracking of enrollment at extramural sites, and additional capabilities were added to enhance reporting and tracking of PMO activity and finally;work has been undertaken to link the database for the clinical trials run by the PMO with that of the Population Studies Facility (PSF). Currently, the PMO is working towards full integration of the Extramural Research Team, which provides monitoring and support to affiliates participating in FCCC-sponsored clinical trials with completion of this project in the next several months.

Public Health Relevance

The ability to safely conduct high-priority clinical research is a mission-critical activity of the Center. The PMO provides a centralized resource that participates at all levels in the activation and conduct of clinical trials, including attention to scientific, ethical, and regulatory issues, protocol compliance, and the objective management of verifiable data for each study.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
7P30CA006927-50
Application #
8475349
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
50
Fiscal Year
2013
Total Cost
$156,840
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Mazor, Anna M; Mateo, Alina M; Demora, Lyudmila et al. (2018) Breast conservation versus mastectomy in patients with T3 breast cancers (>?5 cm): an analysis of 37,268 patients from the National Cancer Database. Breast Cancer Res Treat :
Ingram, Justin P; Tursi, Sarah; Zhang, Ting et al. (2018) A Nonpyroptotic IFN-?-Triggered Cell Death Mechanism in Nonphagocytic Cells Promotes Salmonella Clearance In Vivo. J Immunol 200:3626-3634
Chang, Wen-Chi L; Jackson, Christina; Riel, Stacy et al. (2018) Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas. Gut 67:1290-1298
Mishra, Om P; Popov, Anatoliy V; Pietrofesa, Ralph A et al. (2018) Synthetic secoisolariciresinol diglucoside (LGM2605) inhibits myeloperoxidase activity in inflammatory cells. Biochim Biophys Acta Gen Subj 1862:1364-1375
Mortazavi, S M J; Bevelacqua, J J; Fornalski, K W et al. (2018) Comments on ""Space: The Final Frontier-Research Relevant to Mars"". Health Phys 114:344-345
Esposito, Andrew C; Crawford, James; Sigurdson, Elin R et al. (2018) Omission of radiotherapy after breast conservation surgery in the postneoadjuvant setting. J Surg Res 221:49-57
Dong, Yanqun; Zaorsky, Nicholas G; Li, Tianyu et al. (2018) Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer. J Med Imaging Radiat Oncol 62:116-121
Ge, Yunhui; Borne, Elias; Stewart, Shannon et al. (2018) Simulations of the regulatory ACT domain of human phenylalanine hydroxylase (PAH) unveil its mechanism of phenylalanine binding. J Biol Chem 293:19532-19543
Chow, H Y; Dong, B; Valencia, C A et al. (2018) Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer. Nat Commun 9:3473
Egleston, Brian L; Pedraza, Omar; Wong, Yu-Ning et al. (2018) Temporal trends and characteristics of clinical trials for which only one racial or ethnic group is eligible. Contemp Clin Trials Commun 9:135-142

Showing the most recent 10 out of 1280 publications